Antengene (HKG:6996) posted a loss attributable to owners of 239.1 million yuan for 2025, narrowing from 319.3 million yuan a year earlier, according to a Friday Hong Kong bourse filing.
Loss per share at the pharmaceutical company came in at 0.38 yuan, compared with a loss of 0.51 yuan a year earlier.
Revenue rose year on year to 105.3 million yuan from 92 million yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.